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ABSTRACT
Toxoplasmosis is a life-threatening opportunistic infection that affects haematopoietic stem cell
transplant (HSCT) and solid organ transplant (SOT) recipients. Its incidence in these patients is closely
related to the prevalence of toxoplasmosis in the general population, which is high in Europe. In SOT
recipients, toxoplasmosis results mainly from transmission of the parasite with the transplanted organ
from a Toxoplasma-seropositive donor to a Toxoplasma-seronegative recipient. This risk is high in cases of
transplantation of organs that are recognized sites of encystation of the parasite, e.g. the heart, and is
markedly lower in other SOT recipients. Clinical symptoms usually occur within the ﬁrst 3 months after
transplantation, sometimes as early as 2 weeks post transplant, and involve febrile myocarditis,
encephalitis or pneumonitis. In HSCT recipients, the major risk of toxoplasmosis results from the
reactivation of a pre-transplant latent infection in seropositive recipients. The median point of disease
onset is estimated at 2 months post transplant, with <10% of cases occurring before 30 days and 15–20%
later than day 100. Toxoplasmosis usually manifests as encephalitis or pneumonitis, and frequently
disseminates with multiple organ involvement. Diagnosis of toxoplasmosis is based on the demonstra-
tion of parasites or parasitic DNA in blood, bone marrow, cerebrospinal ﬂuid, bronchoalveolar lavage
ﬂuid or biopsy specimens, and serological tests do not often contribute to the diagnosis. For prevention
of toxoplasmosis, serological screening of donors and recipients before transplantation allows the
identiﬁcation of patients at higher risk of toxoplasmosis, i.e. seropositive HSCT recipients and
mismatched (seropositive donor ⁄ seronegative recipients) SOT recipients. Preventing toxoplasmosis
disease in those patients presently relies on prophylaxis via prescription of co-trimoxazole.
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INTRODUCTION
Toxoplasma gondii is a protozoan parasite with a
worldwide prevalence in the general population
that exceeds 50% in some countries. Human
infection is acquired mainly by ingestion of
undercooked infected meat containing Toxoplasma
cysts or by ingestion of oocysts from faecally
contaminated foods or via poor hand hygiene. In
immunocompetent individuals, acute infection is
usually self-limited and rarely symptomatic,
although some cases of severe infection due to
unusual Toxoplasma genotypes have been re-
ported in South and Central America [1]. The
acute phase of infection is followed by a latent
chronic phase that is characterized by the life-long
persistence of cysts in tissues. The containment of
cysts by speciﬁc immunity is a determiming
factor for this latency, as it has been shown
experimentally that depleting cellular immunity
or cytokine mediators of macrophage activation
results in the reactivation of chronic toxoplasmo-
sis [2]. In humans, the relationship between
immunosuppression and occurrence of severe
toxoplasmosis is well recognized. In human
immunodeﬁciency virus (HIV)-infected patients,
the incidence of toxoplasmic encephalitis is
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closely related to the progression of immunode-
ﬁciency and a decrease in CD4 counts [3,4],
whereas restoration of immunity following highly
active antiretroviral therapy markedly decreases
this incidence [5].
This relationship supports the rationale for
preventing toxoplasmosis in HIV-infected pa-
tients via speciﬁc prophylaxis in patients with
CD counts <100 ⁄mm3 and by initiating highly
active antiretroviral therapy to restore cellular
immunity [6,7].
In non-AIDS immunocompromised patients, the
risk of severe toxoplasmosis is also well recog-
nized. In an extensive review of the literature,
Israelki and Remington [8] identiﬁed 212 cases
between 1953 and 1993, highlighting the high
frequency of life-threatening toxoplasmosis in
organ transplant patients. Since then, the practice
of solid organ and bone marrow transplantation
has markedly progressed, and the conditions of
transplantation, as well as measures undertaken
for prevention of infection, have improved.
Taking into consideration what has been
learned from the management of toxoplasmosis
in AIDS patients, and considering the new
methods for diagnosis of toxoplasmosis, the
objective of this review is to consider the speciﬁc
features of toxoplasmosis in transplant patients,
focusing on practical approaches to diagnosis and
prevention.
PATHOGENESIS OF TOXOPLASMOSIS IN
TRANSPLANT RECIPIENTS
In transplant recipients, toxoplasmosis can result
either from the transmission of the parasite with
the transplanted organ from a Toxoplasma-sero-
positive donor (D+) to a Toxoplasma-seronegative
recipient (R)) or from the reactivation of a pre-
transplant latent infection in a seropositive reci-
pient (R+). Transmission of T. gondii via organ
transplantation from a seropositive donor to a
seropositive recipient seems to be possible. Toxo-
plasma transmission by blood transfusion is
extremely rare.
Graft-transmitted toxoplasmosis
A clear differentiation should be made between
solid organ transplantation (SOT), during which
the risk of transmission is potentially high, and
allogeneic haematopoietic stem cell transplanta-
tion (HSCT), during which this risk is more
theoretical than real (Table 1).
Transmission of T. gondii from a recently infected
donor to a seronegative recipient. This risk of
transmission is related to the possible presence
of T. gondii in the blood and tissue of a donor who
had been infected by T. gondii several days or
weeks before blood ⁄ tissue collection. In that case,
Table 1. Summary of risk factors for toxoplasmosis in transplant patients
Type of risk Clinical disease and prevention
Transmission Reactivation Onset of symptoms Efﬁcient prophylaxis
Haematologous stem cell transplantation
Autologous No risk Very low in R+ 9–120 days ND
Allogenica Possible but no
case reported
High in R+,
regardless of
donor’s serology.
Increased risk in
cord blood SCT
Median: 62 days.
80% of cases in
the second and third
months post-HCST
CTX for pneumocystosis
and toxoplasmosis. Alternatively,
pyrimethamine–sulphadoxine.
Given from day 30 to day 180
after SCT. Prolonged or restarted
in cases of GVHD or sustained
immunosuppression
Solid organ transplantation
Heart ⁄heart–lungb High in mismatched
D+ ⁄R)
Low in R+ 25–195 days CTX given for pneumocystosis
Liverc Low in mismatched
D+ ⁄R)
Low in R+ Median: 24 days in
D+ ⁄R); up to 6 years in R+
CTX given for pneumocystosis
Kidneyc Low in mismatched
D+ ⁄R)
Low in R+ Median: 19 days in
D+ ⁄R), up to 2 months in R+
ND
Intestinec Low in mismatched
D+ ⁄R)
ND 1 case, month 3 ND
Other
(eye, bone, artery)
No risk No risk – –
D, donor; R, recipient; +, positive pretransplant Toxoplasma serology; ), negative pretransplant Toxoplasma serology; ND, not documented; CTX, co-trimoxazole; SCT, stem cell
transplant; HCST, haematopoietic stem cell transplant; GVHD, graft-versus-host disease.
aAdapted from references [12,42,45–47].
bAdapted from reference [25].
cAdapted from reference [32].
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tachyzoites of T. gondii (i.e. the rapidly dividing
stage of the parasite) may be present in the blood,
bone marrow and in various organs, as the early
phase of infection is characterized by a brief
parasitaemia. Several cases of transmission of
T. gondii to SOT patients who received organs
from a single donor whose Toxoplasma serology
was indicative of a recently acquired toxoplas-
mosis have been reported [9,10]. In HSCT, there is
a potential risk of transmission if the donor is
parasitaemic at the time of bone marrow collec-
tion, but, to our knowledge, it has never been
conﬁrmed, although it was suspected in several
cases occurring in pre-transplant seronegative
recipients [11,12].
The duration of the potential risk of transmis-
sion after an acquired infection of the donor is not
known. In animal models of toxoplasmosis, par-
asitaemia can be detected up to 3 weeks following
oral contamination by T. gondii cysts [13]. In
humans, the precise duration of parasitaemia is
not known. One study reported isolation of
T. gondii by mouse inoculation 2 and 14 months
after onset of toxoplasmosis [14]. In a more recent
study using nested PCR, 53% of the patients with
acute toxoplasmic lymphadenopathies had a
detectable parasitaemia 5 weeks after the onset
of symptoms [15].
Transmission from a chronically infected donor to a
seronegative recipient. At the chronic stage of
toxoplasmosis, tissue cysts are formed in the
neural and muscular tissues, including the brain,
eyes, skeletal muscles and cardiac muscles, but
may also develop in visceral organs, including the
lungs, liver and kidneys [16,17]. Their size range
between 10–150 lm in diameter, and they contain
hundreds to thousands of bradyzoites (i.e. the
slowly dividing stage of the parasite). It is believed
that tissue cysts can occasionally rupture without
any clinical symptoms in immunocompetent
hosts, the released bradyzoites being destroyed
by the speciﬁc anti-Toxoplasma immunity [18].
Therefore, some organs taken from a donor
who has been previously infected by T. gondii,
even years before, probably contain cysts. With-
out speciﬁc immunity to T. gondii (seronegative
recipient) and in the context of immunosuppres-
sive therapy for transplant engraftment and tol-
erance, cysts present in the transplanted organ
may be uncontrolled and may rupture, leading to
an active infection. This risk is predominant in
cases of transplantation of organs that are recog-
nized sites of encystation, such as the heart
(striated muscle), and is markedly lower when
other organs are involved. It is estimated that
there is no risk of cyst transmission with haemat-
opoietic stem cells.
Heart and heart–lung transplantation
Since the initial reports in the 1970s [19,20], most
cases of toxoplasmosis in heart and heart–lung
transplantation have been reported in seronega-
tive recipients receiving a heart transplant from a
seropositive donor [8,21–27]. Clinical symptoms
usually occur in the ﬁrst 3 months after trans-
plantation (sometimes as early as 2 weeks post
transplant) and consist of febrile myocarditis,
encephalitis or pneumonitis [8,22,25]. The true
incidence of toxoplasmosis in cases of mismatch
(D+ ⁄R)) is not precisely known but can reach 25–
75% in the absence of prophylaxis (Table 2).
Administration of co-trimoxazole for prophylaxis
of pneumocystosis proved efﬁcient in preventing
toxoplasmosis in cases of mismatch patients
[28,29].
Non-cardiac SOT
Cases of organ-transmitted toxoplasmosis are
much less frequent with organs other than the
heart [8,30,31]. In a recent review of the literature
covering 40 years, Cambpell et al. [32] identiﬁed
52 cases of toxoplasmosis in non-cardiac SOT
recipients (kidney, 34; liver, 12; pancreas, one;
multivisceral, four; small bowel, one), i.e. a very
low risk of toxoplasmosis in light of the number
of such transplantations performed each year
throughout the world. In that review, the sero-
logical status of donors and recipients was avail-
able for 20 ⁄ 52 patients, with a D+ ⁄R) mismatch in
16 cases. In these patients, toxoplasmosis mani-
fested early after transplantation, with a median
time from transplant to symptoms of 21 days
(range 14–28 days). In most cases, serological
data were insufﬁcient to determine whether
transmission from a recently infected donor could
have occurred. However, it is estimated that the
risk of transmission of T. gondii cysts with liver,
kidney, pancreas or intestine from a chronically
infected donor is very low, because T. gondii is not
believed to form persistent cysts in these organs
[32,33].
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Transmission of T. gondii from a seropositive donor to
a seropositive recipient. Cases of severe toxoplas-
mosis have also been observed in seropositive
recipients receiving a heart transplant from a
seropositive donor [34], but this is far less fre-
quent than in cases of mismatch (D+ ⁄R)), sup-
porting the notion that recipient immunity is
protective against the transmission of T. gondii. In
this case, graft transmission is difﬁcult to conﬁrm
and to differentiate from a reactivation of latent
infection in the recipient. However, the hypothe-
sis that a seropositive recipient could be re-
infected by a transplant from a seropositive donor
has been suggested by Robert-Gangneux et al.
[35]. In this study, western blot analysis of post-
transplant sera of seropositive recipients showed
neosynthesized IgG that could be related to the
recognition of a new parasite strain, possibly
acquired via the transplanted organ from a
Toxoplasma-seropositive donor. The only means
of proving this re-infection would be to identify
the infecting strain(s), by serotyping or geno-
typing [36,37].
Reactivation of a latent toxoplasmosis
The reactivation of a previously acquired and
chronic infection is the main cause of toxo-
plasmic encephalitis in AIDS patients, and it
has been closely related to the severity and
progression of immunosuppression. The precise
factors that trigger tissue cyst rupture and
reactivation are largely unknown, but the risk
of occurrence of toxoplasmic encephalitis sharply
increases when the blood CD4 count is below
200 CD4 ⁄mm3.
In transplant recipients, this risk of reactivation
also exists for recipients who are seropositive for
Toxoplasma. It is closely related to the degree and
duration of immunodeﬁciency and, therefore,
markedly differs according to the type of trans-
plantation (Table 1). Moreover, the incidence rate
of Toxoplasma reactivation in transplant patients
varies according to countries, as it is closely
related to the prevalence of toxoplasmosis in the
general population.
HSCT recipients. Allogeneic HSCT recipients are
at very high risk, whereas toxoplasmosis is a rare
event in autologous HSCT recipients [38–41].
Allogeneic HSCT recipients are also at much
higher risk than SOT recipients, because of the
severity of duration of immunosuppression expe-
rienced by these patients. The main risk factors
for toxoplasmosis in HSCT recipients, identiﬁed
in a recent prospective study, were: cord blood
transplantation (as opposed to other sources of
stem cells), advanced underlying disease, anti-
thymocyte globulin during a conditioning regi-
men, receipt of an organ from a seronegative
donor, and lack of appropriate prophylaxis. In
multivariate analysis, only cord blood transplan-
tation, which is associated with a very severe and
protracted immunocompromised status, retained
statistical signiﬁcance [42].
From several reviews and case reports [12,42–
48], the median time to disease onset can be
estimated at 2 months post-HSCT, with fewer
than 10% of cases occurring before 30 days and
15–20% later than day 100 (Fig. 1). Therefore, the
risk of Toxoplasma reactivation in seropositive
recipients is particularly high during the
2–4 months post transplant. It can be prolonged
to 6 months, and is even longer in cases of
delayed immune reconstitution and occurrence
of graft-versus-host disease.
Table 2. Reported prevalence of organ-transmitted and reactivated toxoplasmosis in heart and heart–lung transplant
recipients in various countries
Country
Transmission in seronegative recipients Reactivation in seropositive recipients
Reference
Number of
seronegative
recipients
Number of
D+ ⁄R)
mismatches
Clinical toxoplasmosis
(prevalence)
Number of
seropositive
recipients
Serological
reactivations
(prevalence)
Clinical
toxoplasmosis
USA 509 (84%) 32 4 (12.5%; 25% in the
16 patients without prophylaxis)
98 (16%) ND 0 ⁄ 98 Montoya et al. [27]
USA 31 (62%) 4 3 (75%) 19 (38%) 10 ⁄ 19 (52.6%) 0 Luft et al. [21]
Switzerland 52 (43%) 18 3 (16.7%) 69 (57%) 5 ⁄ 69 (7.2%) 2 ⁄ 5 Gallino et al. [24]
UK 175 (70%) 21 6 (28.5%; 57% in the
four of seven patients
without prophylaxis)
75 (30%) 3 ⁄ 75 (4%) 2 ⁄ 3 Wregitt et al. [22]
France 23 (36%) ND 0 42 (64%) 10 (23.8%) 0 Lavarde et al. [59]
D+, seropositive donor; R), seronegative recipient; ND, not documented.
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The extreme severity of the disease is high-
lighted in most studies and case reports, and the
mortality rate is high. Toxoplasmic encephalitis
presenting with brain abscesses is the most
frequent initial presentation [48,49], but diffuse
brain lesions and meningitis have also been
reported [45,50,51]. Pneumonitis, including acute
distress syndrome and disseminated toxoplasmo-
sis with multiple organ involvement, is frequently
reported in autopsies [12,52,53], and has been
associated with a haemophagocytic syndrome in
some cases [54].
The true incidence of toxoplasmosis in HSCT
recipients is difﬁcult to estimate, because diagno-
sis is difﬁcult, and autopsy records indicate that
cases might have been misdiagnosed. The
reported incidence markedly varies from 0.2%
to 4% according to HSCT centre, with higher rates
of incidence being seen in countries where the
prevalence of toxoplasmosis is high in the general
population. However, if only the seropositive
recipients are considered, the range of incidences
among countries is more narrow (1.9–5.7%)
(Table 3) [40,42,44–47,55,56].
It has been suggested that the serological status
of the donor could inﬂuence the risk of occurrence
of reactivation, as approximately 80% of reported
cases of toxoplasmosis are observed in patients
whose donor was seronegative for T. gondii
(D) ⁄R+) [42,43,45]. However, the protective func-
tion of the grafted cell from a seropositive donor
is very uncertain, as the immune reconstitution of
the recipient by the donor’s cell is delayed and
incomplete. Thus, even if a D) ⁄R+ mismatch
represents a potentially greater risk factor, any
seropositive recipient should be considered to be
at high risk of reactivation.
SOT recipients. Reactivation of latent Toxoplasma
infections occurs in SOT seropositive recipients,
but is far less frequent and less severe than in
HSCT recipients [57]. In cases of heart and
heart–lung transplantation, the rates of reactiva-
tion markedly vary according to country and
transplant centre; reactivation is mainly sero-
logical, with clinical symptoms of toxoplas-
mosis manifesting occasionally [21,22,24,27,58,59]
(Table 2).
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Fig. 1. Onset of toxoplasmosis in 81
allogeneic stem cell transplant (SCT)
recipients; adapted from references
[12,42,45–47].
Table 3. Reported prevalence of
toxoplasmosis in haematopoietic
stem cell transplant recipients in
various countries
Country
Number
of patients
Toxoplasma
seroprevalence
(number of
seropositive
patients)
Clinical toxoplasmosis
Reference
Number
of cases
Prevalence
(%) global/in
seropositive
patients
Japan 925 10%a (93) 2 0.2 ⁄ 2.1 Matsuo et al. [40]
USA 3803 15%b (570) 12 0.3 ⁄ 2.1 Slavin et al. [46]
Brazil 786 60%b (472) 9 1.1 ⁄ 1.9 De Meddeiros et al. [47]
France 296 68%b (201) 7 2.4 ⁄ 3.5 Derouin et al. [45]
Germany 75 71% (53) 3 4.0 ⁄ 5.7 Janitschke et al. [56]
France 106 100% (106)c 6 ND ⁄ 5.7 Martino et al. [42]
ND, not documented.
aEstimated prevalence in Japan provided in [40].
bEstimated from a fraction of patients.
cStudy restricted to Toxoplasma gondi-seropositive patients.
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In non-cardiac SOT recipients, clinical toxo-
plasmosis is a rare event. In a recent extensive
review of the literature, Campbell et al. recorded
34 cases of clinical toxoplasmosis in kidney
transplant recipients, of which eight could be
related to reactivation [32]. Among liver trans-
plant recipients, three cases of toxoplasmosis
related to reactivation have been reported.
Asymptomatic serological reactivations might
be much more frequent, as observed in seven of
49 seropositive renal transplant recipients and
eight of 25 liver transplant recipients in two
French centres [60,61].
Considering the number of SOTs performed
throughout the world, the number of reported
cases of clinical toxoplasmosis is very low. How-
ever, clinicians should be aware of the risk in
seropositive recipients, especially those receiving
aggressive immunosuppressive therapy. In these
patients, the risk of re-infection has also been
hypothesized but needs to be further assessed by
strain genotyping.
DIAGNOSIS
The diagnosis of toxoplasmosis in transplant
recipients is often difﬁcult. From a clinical point
of view, the features of reactivated or transmit-
ted toxoplasmosis are not speciﬁc, with fever
being the main sign, associated with various
other signs that are dependent on the dissemi-
nation of the parasite. Imaging by computed
tomography, or preferably by magnetic reso-
nance imaging, provides strong support for a
diagnosis of toxoplasmic encephalitis. Focal
necrosis is the most common presentation, with
single or multiple contrast-enhancing lesions
with hypodensities, surrounded by oedema; a
mass effect may be present, with displacement of
the ventricle (Fig. 2). However, as stated earlier,
lesions may be non-focal (diffuse encephalitis) or
atypical. Pulmonary toxoplasmosis usually man-
ifests as interstitial pneumonitis with alveolar
condensations, and is frequently associated with
signs of dissemination and with multiple organ
involvement or failure.
The serological diagnosis of toxoplasmosis has
important limitations, as the underlying immu-
nosuppression alters antibody production and its
kinetics. The demonstration of parasites in blood,
body ﬂuids and tissues is the mainstay of diag-
nosis, providing deﬁnitive proof of the disease.
One must not forget that the demonstration of
tachyzoites by microscopic examination of Giem-
sa-stained smears of bone marrow aspirates or
bronchoalveolar lavage ﬂuid remains the simplest
and most rapid means of diagnosis of dissemi-
nated toxoplasmosis. Diagnosis can also rely on
the demonstration of tachyzoites and cysts in
haematoxylin- or Giemsa-stained tissue biopsy
specimens, preferentially using immunohisto-
chemistry [62,63]. Because of the low sensitivity
of direct microscopic methods, enrichment meth-
ods should be used in association with micro-
scopy. Mouse inoculation is the reference
technique, allowing strain isolation and possible
genotyping, but a deﬁnitive result can only be
obtained 4 weeks post inoculation. Cell culture
offers the possibility of reducing this delay, but is
no longer used for diagnosis, since the develop-
ment of DNA-based diagnostic methods. PCR
techniques, the most sensitive of which involve
the repeated B1 and AF146527 gene targets, have
markedly changed the strategy for diagnosis and
treatment of transplant recipients [42,64–68].
Moreover, the use of real-time PCR avoids the
risk of false positivity due to DNA carryover [65],
and allows quantiﬁcation of T. gondii DNA to
monitor treatment efﬁcacy [50].
In 2000, the Infectious Diseases Working Party
of the European Group for Blood and Marrow
Transplantation deﬁned ‘probable toxoplasmo-
sis’ as the observation of ‘clinical and radiological
evidence suggestive of organ involvement plus at
least one positive PCR result from blood, CSF, or
BAL, but no histologic conﬁrmation and absence
of another pathogen that may explain the
Fig. 2. Source: CD-ROM ANOFEL 3 and courtesy of
Professor J. Frija, Service de Radiologie, Hoˆpital Saint-
Louis, Paris, France.
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ﬁndings’ [49]. The existence of a positive PCR
result from blood, without evidence of organ
involvement, should be considered as only a
possible diagnosis of toxoplasmosis. A negative
PCR result has a good negative predictive value,
as demonstrated by the results of the large
prospective study by Martino et al. [42], in which
none of the stem cell transplant recipients for
whom PCR from blood was negative developed
toxoplasmosis.
However, a negative PCR result cannot rule out
the diagnosis of toxoplasmosis, as cases of toxo-
plasmosis have also been reported with negative
PCR results from blood [63,65]. The negative
predictive value of PCR results from blood might
also be dependent on the timing and the repeti-
tion of blood sampling.
Diagnosis of organ-transmitted infection. Organ-
transmitted infection can be suspected in cases
of serological mismatch (D+ ⁄R)). A seroconver-
sion occurring early after transplant, with dem-
onstration of IgM and IgG antibodies, and
eventually IgA and IgE [69], is a strong indication
of an acquired (and probably transmitted) infec-
tion with subsequent risk of disease. In cases of
profound immunosuppression, the antibody re-
sponse might be lacking or atypical, and diagno-
sis can be based only on the demonstration of
parasites or parasite DNA in blood, body ﬂuids or
biopsy specimens, guided by clinical symptoms
[67]. In HSCT recipients, seroconversion with the
appearance of IgG and IgM antibodies has rarely
been reported, whereas a transient increase of IgG
antibodies at a low titre (<100 IU ⁄mL and without
IgM) is more frequent and probably related to
passive antibody transmission via the graft or
blood transfusions [55].
Diagnosis of reactivation. A reactivation should be
suspected upon observation of a rise in speciﬁc
antibody titres, usually IgG antibodies without
IgM or IgA antibodies [70]. IgG antibodies
produced during reactivation have a high avid-
ity index, indicating an immune recall rather
than a primary immune response [71]. The
appearance of IgM antibodies is occasionally
observed in HSCT recipients, possibly as a
primary immune response of grafted cells from
seronegative donors. However, there is no clear
relationship between serological reactivation in a
seropositive recipient and clinical disease.
Among cardiac transplant recipients, clinical
symptoms indicative of toxoplasmosis have been
reported at the time of antibody increase in two
of ﬁve patients by Gallino et al. [24] and two of
four patients by Wregitt et al. [22], but were not
reported in other studies in which high rates of
serological reactivation have been observed
[21,59] (Table 2). Among renal transplant recip-
ients, an antibody increase was observed in 5–
10% of patients and was not associated with, or
followed by, clinical symptoms indicative of
toxoplasmosis [60,72]. Among HSCT recipients,
serological reactivations that occur late after
transplantation (10–18 months post-HSCT) are
frequent and usually asymptomatic [55].
The diagnosis of reactivation is even more
difﬁcult in patients who develop clinical toxo-
plasmosis when antibody titres remain stable
after transplant. This is the most frequent
situation in HSCT recipients. In these cases, no
conclusion can be drawn from the results of
serological tests, and diagnosis must be based
on imaging and the demonstration of parasites
or parasitic DNA. As stated earlier, the proof of
infection is provided only by the demonstration
of tachyzoites in blood, bone marrow, bronc-
hoalveolar lavage ﬂuid, cerebrospinal ﬂuid or
tissue biopsy specimens using microscopy,
mouse inoculation or PCR techniques. Indeed,
a positive PCR result is indicative of reactiva-
tion, but should be interpreted in the context of
clinical symptoms and with the understanding
that asymptomatic transient positive reactions
can be observed after HSCT [64].
PREVENTION AND PROPHYLAXIS OF
TOXOPLASMOSIS IN TRANSPLANT
RECIPIENTS
Toxoplasmosis represents a major infectious com-
plication in transplant recipients that should be
prevented, and three complementary approaches
to prevention can be proposed.
Serological screening of donor and recipients
The determination of the Toxoplasma serological
status of donors and recipients provides critical
information concerning the potential risk of toxo-
plasmosis following transplantation. This test is
inexpensive, and allows discrimination among
three categories of risk: (i) the potential risk of
Derouin and Pelloux Toxoplasmosis in transplant patients 1095
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14, 1089–1101
transmission in SOT recipients in cases of mis-
match (D+ ⁄R)) and in seronegative HSCT recip-
ients in cases of recently acquired infection of the
donor; (ii) the risk of reactivation for seropositive
HSCT and SOT recipients (independent of the
serology of the donor); and (iii) the low risk of
toxoplasmosis if both donor and recipient are
seronegative. In the latter case, the only risk is
contamination via ingestion of cysts with under-
cooked meat or oocysts with insufﬁciently
washed foods, or via poor hand hygiene.
In Europe, Toxoplasma serology is undertaken
according to the practice of the respective
transplant center (ESGP information). In some
countries, e.g. France, the test for Toxoplasma is
included among the serological tests legally
required for every organ donor and is strongly
recommended for recipients prior to transplanta-
tion. Among 29 countries participating in the
Eurotransplant network, Toxoplasma serology is
routinely undertaken for SOT donors in 11 and is
undertaken according to the characteristics of the
donor in ten [73].
In the USA, serological screening of donors is
not mandatory, and routine screening of donors
and recipients largely depends on the transplant
centre (J. S. Remington, personal communication).
Recent publications indicate that routine
screening may be unnecessary because, for years,
no case of toxoplasmosis has been observed
among heart transplant recipients treated pro-
phylactically with co-trimoxazole for prevention
of pneumocystosis [29,74]. Indeed, the remark-
able prophylactic efﬁcacy of co-trimoxazole must
be acknowledged, but there is a potential risk of
toxoplasmosis if co-trimoxazole prophylaxis is
suspended or replaced by pentaminide prophy-
laxis, which has no effect on T. gondii. Owing to
the low cost of the serological test and the
beneﬁt provided in terms of risk management,
we propose that a serological test should be
performed in all transplant donors and recipi-
ents. In cases of HSCT, the serological status of
both donor and recipient should be determined
before transplantation, because of the early and
high risk of toxoplasmosis following transplan-
tation. In cases of SOT, which involves a lower
risk of toxoplasmosis, a possible alternative
would be to store both donor and recipient
pre-transplant sera and perform serological test-
ing only in cases of clinical suspicion of toxo-
plasmosis [74].
Serological and PCR follow-up of patients after
transplant
A serological follow-up is informative in cases of
SOT mismatched recipients (D+ ⁄R)), as the obser-
vation of a seroconversion clearly indicates trans-
mission of T. gondii. In other SOT and HSCT
recipients, such follow-up has little beneﬁt, as an
antibody increase does not reliably indicate a
progressive disease. A PCR follow-up of patients
at risk might be more informative, as a positive
PCR result can be an early sign of disease
[42,64,75]. However, because of the high cost of
PCR testing, the indications and the timing of
PCR follow-up should probably be restricted to
deﬁned high-risk periods and to patients who do
not receive prophylaxis. This follow-up recom-
mended in Toxoplasma-seropositive HSCT recipi-
ents who do not tolerate co-trimoxazole (or other
anti-Toxoplasma drugs) and thus receive penta-
midine for prevention of pneumocystosis, and
recipients of unrelated cord blood transplants,
because of their high risk of reactivating toxo-
plasmosis.
Chemoprophylaxis
Considering the severity and rapid progression of
toxoplasmosis in SOT and HSCT recipients,
administration of primary chemoprophylaxis to
high-risk patients should be considered.
The ideal drug for prophylaxis would be able
to eradicate cysts, would be preferentially par-
asiticidal against the different parasitic stages,
would be well distributed in the main sites of
infection, and would be well tolerated. No such
drug exists. Presently, there is no drug with
proven efﬁcacy against tissue cysts. Atovaquone
has been found to reduce the number of brain
cysts in chronically infected mice [76], but this
effect has not been (and probably cannot be)
conﬁrmed in humans.
Other drugs are effective only on the tachyzo-
ite, which is the highly replicative stage of the
parasite that is present at the acute phase of
infection and during reactivation. Among these
drugs, folate inhibitors (dihydrofolate reductase
inhibitors, sulphonamides) as well as atovaquone
are strongly parasiticidal and are rapidly effective
against tachyzoites in vitro and in vivo. Macro-
lides (spiramycine, clarithromycin, roxithro-
mycin, azithromycin) and related drugs
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(clindamycin) have a delayed antiparasitic effect
and are not adapted for the containment of an
active infection [77]. The possible innate resis-
tance of some genotypes of T. gondii and the risk
of selecting drug-resistant parasites via long-term
prophylaxis have been suggested for T. gondii, as
for Pneumocystis and Plasmodium. Drug-resistant
isolates of T. gondii can be obtained in vitro by
mutagenesis, but there is no documented proof of
such selection in humans. Recently, the study of
17 strains (15 of human origin) belonging to
various genotypes of T. gondii revealed similar
susceptibilities to pyrimethamine and atova-
quone, whereas three strains were resistant
to sulphadiazine, without evidence of mutation
on the target dyhidropteroate synthase (DHPS)
gene, or a relationship with the parasite genotype
[78].
Presently, the combination of a dihydrofolate
reductase inhibitor and a sulphonamide is the
most efﬁcient prophylaxis for toxoplasmosis, as
both compounds are highly synergistic against
T. gondii. Pyrimethamine alone has been
proposed for prophylaxis for toxoplasmosis in
heart transplant recipients [22,26], but this drug
is at least ten-fold less efﬁcient alone than
in combination with a sulphonamide. Two drug
combinations proved efﬁcient in preventing
toxoplasmosis in transplant recipients: tri-
methoprim–sulphamethoxazole (co-trimoxazole)
[29,74,79,80] and pyrimethamine–sulphadoxine
[80]. Both combinations have undesirable side
effects, related to sulphonamides (skin rashes,
nephrotoxicity and, rarely, Lyell syndrome with
pyrimethamine–sulphadoxine) and related to
the folate inhibitor (myelotoxicity). Myelotoxic-
ity can usually be prevented by concomitant
administration of folinic acid (leucovorin) and
adaptation of the dosage to the renal clearance.
Atovaquone alone proved efﬁcient for second-
ary prophylaxis of toxoplasmosis in AIDS
patients [81], and proved to be both efﬁcient
and well tolerated in autologous HSCT recipi-
ents for prevention of pneumocystosis [82].
However, its use as primary prophylaxis for
toxoplasmosis is limited by its poor intestinal
absorption and risk of failure under therapy
[83].
Prophylaxis in HSCT recipients. Prophylaxis prior
to transplantation is recommended for all recip-
ients who are seropositive for Toxoplasma.
Co-trimoxazole is the recommended drug in the
USA [84,85] and the most widely used drug in
European HSCT centres [44]. Pyrimethamine–
sulphadoxine is preferred in some centres [80],
as it can be administered weekly rather than once-
daily or two or three times weekly, which is the
regimen for co-trimoxazole. For patients who are
intolerant to co-trimoxazole, a combination of
clindamycin, pyrimethamine and leucovorin has
been proposed [84], but this combination exposes
the patient to myelosupression. Atovaquone
could be a safe alternative, but its efﬁcacy has
not been evaluated. There is no consensus con-
cerning initiation and duration of prophylaxis.
Starting prophylaxis immediately after HSCT
exposes the patient to some degree of toxicity
with regard to grafted cells and delayed engraft-
ment, whereas delaying prophylaxis places the
patient at risk for toxoplasmosis. A delay of
30 days after HSCT before initiation of prophy-
laxis seems reasonable, as 90% of the cases of
toxoplasmosis occur 30 days post-HSCT. If
delayed prophylaxis is preferred, a weekly
follow-up of the recipient using PCR with
peripheral blood is recommended for high-risk
patients during the entire period without
prophylaxis.
With regard to the incidence rate of toxoplas-
mosis following HSCT, prophylaxis should be
maintained for 6 months post-HSCT. It should
be prolonged in cases of graft-versus-host dis-
ease, prolonged neutropenia and prolonged
administration of corticosteroids. If prophylaxis
must be suspended because of drug intolerance,
a close follow-up by PCR should be instituted.
HSCT recipients who are seronegative are at
very low risk of acquiring toxoplasmosis, but they
should be advised of the risk of acquiring toxo-
plasmosis via ingestion of undercooked meat
(possibly containing cysts) or raw vegetables
(possibly contaminated by oocysts). A low but
potential risk of transmission via the stem cell
graft from a recently infected donor should be
taken into account if the donor’s serology shows a
pattern of recently acquired infection, i.e. pres-
ence of IgM, low avidity of IgG antibodies, and
increasing IgG titre. In this case, the proposed
procedure is: (i) to treat the donor, if possible,
using a short course of drugs that rapidly erad-
icate parasitaemia, e.g. pyrimethamine combined
with sulphadiazine; (ii) to assess the collected
haematopoietic stem cells by PCR; and (iii) to
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initiate prophylaxis in the HSCT recipient follow-
ing transplantation [86].
Prophylaxis in SOT recipients. The risk of transmis-
sion of T. gondii is almost restricted to mis-
matched patients, i.e. D+ ⁄R–, and is limited to
a several-month period post transplantation.
Co-trimoxazole is the drug of choice for prophy-
laxis. Its efﬁcacy has been established in studies in
which it was used for prophylaxis of pneumo-
cystosis [29,74]. In cases of intolerance to sulph-
onamides, a possible alternative is the use of
pyrimethamine alone [22,26]. The risk of reacti-
vation of a latent toxoplasmosis is very low in
SOT seropositive recipients, and does not justify a
speciﬁc prophylaxis regimen in addition to that
for pneumocystosis. However, the potential risk
of reactivation of toxoplasmosis should not be
ignored in patients who are no longer receiving
prophylaxis for pneumocystosis.
CONCLUSION
Toxoplasmosis remains one of the most severe
opportunistic infections occurring after transplan-
tation, with a high mortality rate in cases of
delayed diagnosis. It should be stressed that at
least 75% of the cases occur in patients who have
not received prophylaxis, emphasizing the need
to make available updated information concern-
ing the pathogenesis of toxoplasmosis, the proce-
dures for identiﬁcation of risk factors and the
measures for prevention. The combination of
serological screening of donors and recipients,
chemoprophylaxis in patients susceptible to reac-
tivation or exposed to organ transmission of
T. gondii and PCR follow-up of high-risk patients
should be effective in reducing the occurrence of
toxoplasmosis in transplant recipients.
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